References
1.
The
Writing Committee Of The Report On Cardiovascular Health And Diseases In
China. Hu SS. Report on cardiovascular health and diseases in China
2021: an updated summary. J Geriatr Cardiol 2023;20:399-430.
2. Lu J, Lu Y, Wang X, et al.
Prevalence, awareness,
treatment, and control of hypertension in China: data from 1·7 million
adults in a population-based screening study (China PEACE Million
Persons Project). Lancet 2017;390:2549-58.
3. Hu C. Grants supporting research in China. Eur Heart J
2018;39:2342-4.
4. Hu C. C-type Hypertension. Eur Heart J 2019;40:715.
5. Hu C, Wu Y, Li J, et al. Hypertension associated with unhealthy
lifestyle and marked by serum cortisol levels. Res Sq (preprint). 26
Aug, 2021. https://www.researchsquare.com/article/rs-824235/v1
6. Hu CS, Tkebuchava T. E-noise: An increasingly relevant health risk. J
Integr Med 2019;17:311-4.
7. Hu C. Health is the first capital– A new concept from CHINA.
Manuscript in Submission.
8. Global Cardiovascular Risk Consortium; Magnussen C, Ojeda FM, Leong
DP, et al. Global
Effect of Modifiable Risk Factors on Cardiovascular Disease and
Mortality. N Engl J Med 2023;389:1273-85.
9. Jafar TH, Islam M, Bux R, et al. Hypertension Research Group.
Cost-effectiveness of
community-based strategies for blood pressure control in a low-income
developing country: findings from a cluster-randomized,
factorial-controlled trial. Circulation 2011;124:1615-25.
10. McManus RJ, Little P, Stuart B, et al. HOME BP investigators.
Home and Online
Management and Evaluation of Blood Pressure (HOME BP) using a digital
intervention in poorly controlled hypertension: randomised controlled
trial. BMJ 2021;372:m4858.
11. Monahan M, Jowett S, Nickless A, et al.
Cost-Effectiveness of
Telemonitoring and Self-Monitoring of Blood Pressure for
Antihypertensive Titration in Primary Care (TASMINH4). Hypertension
2019;73:1231-9.
12. Boubouchairopoulou N, Karpettas N, Athanasakis K, et al.
Cost estimation
of hypertension management based on home blood pressure monitoring alone
or combined office and ambulatory blood pressure measurements. J Am Soc
Hypertens 2014;8:732-8.
13. Kaambwa B, Bryan S, Jowett S, et al.
Telemonitoring and
self-management in the control of hypertension (TASMINH2):
a cost-effectiveness analysis. Eur J Prev Cardiol 2014;21:1517-30.
14. Søgaard R, Diederichsen ACP, Rasmussen LM, et al.
Cost effectiveness of
population screening vs. no screening for cardiovascular disease: the
Danish Cardiovascular Screening trial (DANCAVAS). Eur Heart J
2022;43:4392-402.
15. Li KC, Huang L, Tian M, et al.
Cost-Effectiveness of a
Household Salt Substitution Intervention: Findings From 20 995
Participants of the Salt Substitute and Stroke Study. Circulation
2022;145:1534-41.
16. Henry A, Arnott C, Makris A, et al.
Blood pressure
postpartum (BP2) RCT protocol: Follow-up and lifestyle
behaviour change strategies in the first 12 months after hypertensive
pregnancy. Pregnancy Hypertens 2020;22:1-6.
17. Zomer E, Owen A, Magliano DJ, Liew D, Reid CM.
The effectiveness and cost effectiveness of
dark chocolate consumption as prevention therapy in people at high risk
of cardiovascular disease: best case scenario analysis using a Markov
model. BMJ 2012;344:e3657.
18. Zhang T, Liang Z,
Lin T, et al. Cost-effectiveness of folic acid therapy for primary
prevention of stroke in patients with hypertension. BMC Med
2022;20:407.
19. Maniadakis N, Ekman
M, Fragoulakis V, Papagiannopoulou V, Yfantopoulos J.
Economic evaluation of irbesartan in combination with
hydrochlorothiazide in the treatment of hypertension in Greece. Eur J
Health Econ 2011;12:253-61.
20. Grosso AM, Bodalia PN, Macallister RJ, Hingorani AD, Moon JC, Scott
MA.
Comparative clinical-
and cost-effectiveness of candesartan and losartan in the management
of hypertension and heart failure: a systematic review, meta-
and cost-utility analysis. Int J Clin Pract 2011;65:253-63.
21. Freeman MW, Halvorsen YD, Marshall W, et al. BrigHTN Investigators.
Phase 2 Trial of
Baxdrostat for Treatment-Resistant Hypertension. N Engl J Med
2023;388:395-405.
22. Laffin LJ, Rodman D, Luther JM, et al. Target-HTN Investigators.
Aldosterone Synthase
Inhibition With Lorundrostat for Uncontrolled Hypertension: The
Target-HTN Randomized Clinical Trial. JAMA 2023;330:1140-50.
23. Desai AS, Webb DJ, Taubel J, et al.
Zilebesiran, an RNA
Interference Therapeutic Agent for Hypertension. N Engl J Med
2023;389:228-38.
24. Azizi M, Saxena M, Wang Y, et al.
Endovascular Ultrasound
Renal Denervation to Treat Hypertension: The RADIANCE II Randomized
Clinical Trial. JAMA 2023;329:651-61.
25. Fan J, Zheng W, Liu W, et al.
Cost-Effectiveness of
Intensive Versus Standard Blood Pressure Treatment in Older Patients
With Hypertension in China. Hypertension 2022;79:2631-41.
26. Derington CG, King JB, Bryant KB, et al.
Cost-Effectiveness and
Challenges of Implementing Intensive Blood Pressure Goals and Team-Based
Care. Curr Hypertens Rep 2019;21:91.
27. Zhang Y, Yin L, Mills K, et al.
Cost-effectiveness of a
Multicomponent Intervention for Hypertension Control in Low-Income
Settings in Argentina. JAMA Netw Open 2021;4:e2122559.
28. Finkelstein EA, Krishnan A, Naheed A, et al. COBRA-BPS study group.
Budget impact and
cost-effectiveness analyses of the COBRA-BPS multicomponent hypertension
management programme in rural communities in Bangladesh, Pakistan, and
Sri Lanka. Lancet Glob Health 2021;9:e660-7.
29. Augustovski F,
Chaparro M, Palacios A, et al. Cost-Effectiveness of a Comprehensive
Approach for Hypertension Control in Low-Income Settings in Argentina:
Trial-Based Analysis of the Hypertension Control Program in Argentina.
Value Health 2018;21:1357-64.
30. Jafar TH, Tan NC, Allen JC, et al.
Management of
hypertension and multiple risk factors to enhance cardiovascular health
in Singapore: The SingHypertension cluster randomized trial. Trials
2018;19:180.
31. Marra C, Johnston K, Santschi V, Tsuyuki RT.
Cost-effectiveness of
pharmacist care for managing hypertension in Canada. Can Pharm J (Ott)
2017;150:184-97.
32. Penaloza-Ramos MC, Jowett S, Mant J, et al.
Cost-effectiveness of
self-management of blood pressure in hypertensive patients over 70 years
with suboptimal control and established cardiovascular disease or
additional cardiovascular risk diseases (TASMIN-SR). Eur J Prev Cardiol
2016;23:902-12.
33. Li T, Ding W, Li X, Lin A.
Mobile health
technology (WeChat) for the hierarchical management of community
hypertension: protocol for a cluster randomized controlled trial.
Patient Prefer Adherence 2019;13:1339-52.
34. Anchala R, Kaptoge S, Pant H, Di Angelantonio E, Franco OH,
Prabhakaran D.
Evaluation
of effectiveness and cost-effectiveness of a clinical decision
support system in managing hypertension in resource constrained primary
health care settings: results from a cluster randomized trial. J Am
Heart Assoc 2015;4:e001213.
35. Smith SM, Campbell JD.
Cost-effectiveness of
renin-guided treatment of hypertension. Am J Hypertens
2013;26:1303-1310.
36. Penaloza-Ramos MC, Jowett S, Barton P, et al.
Cost-effectiveness analysis of
different systolic blood pressure targets for people with a history of
stroke or transient ischaemic attack: Economic analysis of the PAST-BP
study. Eur J Prev Cardiol 2016;23:1590-8.
37. Gu D, He J, Coxson PG, et al.
The Cost-Effectiveness of
Low-Cost Essential Antihypertensive Medicines for Hypertension Control
in China: A Modelling Study. PLoS Med 2015;12:e1001860.
38. Ma W, Sun N, Duan C, et al. for LEADER Study Group.
Effectiveness of
Levoamlodipine Maleate for Hypertension Compared with Amlodipine
Besylate: a Pragmatic Comparative Effectiveness Study. Cardiovasc Drugs
Ther 2021;35:41-50.
39. Li C, Chen K, Cornelius V, et al.
Applicability and
cost-effectiveness of the Systolic Blood Pressure Intervention Trial
(SPRINT) in the Chinese population: A cost-effectiveness modeling
study. PLoS Med 2021;18:e1003515.
40. Ghazi L, Oparil S.
Impact of the SPRINT
Trial on Hypertension Management. Annu Rev Med 2018;69:81-95.
41. Oseran AS, Sun T, Wadhera RK.
Health Care Access and
Management of Cardiovascular Risk Factors Among Working-Age Adults With
Low Income by State Medicaid Expansion Status. JAMA Cardiol
2022;7:708-14.
42. Berman AN, Biery DW, Ginder C, et al.
Association of
Socioeconomic Disadvantage With Long-term Mortality After Myocardial
Infarction: The Mass General Brigham YOUNG-MI Registry. JAMA Cardiol
2021;6:880-8.
43. Richman IB, Fairley M, Jørgensen ME, Schuler A, Owens DK,
Goldhaber-Fiebert JD.
Cost-effectiveness of
Intensive Blood Pressure Management. JAMA Cardiol 2016;1:872-9.
44. Lewey J, Murphy S, Zhang D, et al.
Effectiveness of a
Text-Based Gamification Intervention to Improve Physical Activity Among
Postpartum Individuals With Hypertensive Disorders of Pregnancy: A
Randomized Clinical Trial. JAMA Cardiol 2022;7:591-9.
45. Cao DY, Giani JF, Veiras LC, et al.
An ACE inhibitor
reduces bactericidal activity of human neutrophils in vitro and impairs
mouse neutrophil activity in vivo. Sci Transl Med 2021;13:eabj2138.
46. Xu X, Kawakami J, Millagaha Gedara NI, et al.
Data mining methodology
for response to hypertension symptomology-application
to COVID-19-related pharmacovigilance. Elife 2021;10:e70734.
47. Shen Q, Zhang H, Huang Y, et al.
Sensitive detection of
single-nucleotide polymorphisms by conjugated polymers for personalized
treatment of hypertension. Sci Transl Med 2023;15:eabq5753.
48. Li X, Krumholz HM, Yip W, et al.
Quality of
primary health care in China: challenges and recommendations. Lancet
2020;395:1802-12.
49. Hu C, Wu Q. Health:
a dream from reality to the future. Front Med 2016;10:233-5.
50. Hu CS. Intervention of RT-ABCDEF for cancer. Croat Med J
2019;60:55-7.
51. Hu C, Tkebuchava T.
Health in All Laws: A better strategy for global health. J Evid Based
Med 2022;15:10-4.